Landscape of current and future therapies of Merkel cell carcinoma

Area of Science:

• Oncology
• Dermatology
• Immunology

Background:

• Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with ultraviolet light and Merkel-cell polyomavirus (MCPyV).
• Understanding MCC pathogenesis has advanced, revealing PD-L1 expression in tumors and PD-1 on MCPyV-specific T cells.
• This suggests potential efficacy of PD-1/PD-L1 checkpoint inhibition therapies.

Purpose of the Study:

• To review current and future therapeutic strategies for Merkel cell carcinoma.
• To highlight the role of PD-1/PD-L1 checkpoint inhibitors in MCC treatment.
• To identify the need for innovative therapies beyond current standards of care.

Main Methods:

• Review of current literature on Merkel cell carcinoma pathogenesis and treatment.
• Analysis of the role of PD-1/PD-L1 checkpoint inhibitors in clinical trials for MCC.
• Discussion of emerging therapeutic approaches.

Main Results:

• PD-1/PD-L1 checkpoint therapies are a promising treatment option for advanced MCC.
• Clinical trials are ongoing to establish the effectiveness and safety of these therapies.
• Current therapies achieve remission or stabilization in approximately 50% of advanced MCC patients.

Conclusions:

• PD-1/PD-L1 checkpoint inhibitors represent a significant advancement in MCC treatment.
• Despite progress, innovative therapeutic strategies are essential for improving patient outcomes.
• Further research and clinical trials are crucial for developing novel MCC treatments.